GALD.SW stock down 2.11% to CHF143.80 on heavy volume: analyst view ahead

GALD.SW stock closed at CHF143.80 on the SIX in Switzerland on 13 Mar 2026, down -2.11% on 3,001,105.00 shares. The move came on above-average volume, with relative volume 2.95, and a day range between CHF143.40 and CHF148.30. Investors are watching valuation and margin metrics after recent volatility. We look at price action, fundamentals, technicals, and short-term catalysts to explain why this Consumer Defensive name shows mixed signals.

GALD.SW stock: Price action and trading activity

Galderma Group N (GALD.SW) finished the session at CHF143.80, down CHF3.10. Volume hit 3,001,105.00, almost three times the average 1,019,959.00, showing strong investor interest today. The stock opened at CHF148.00 and traded within a CHF4.90 range. Year high sits at CHF170.10 and year low at CHF72.70, underlining a wide trading band since IPO.

GALD.SW stock: Valuation and financials

Galderma reports EPS of CHF2.01 and a reported PE of 71.54, with trailing key ratios showing price-to-sales 4.99 and price-to-book 2.72. Market capitalization is CHF33,767,669,342.00, and free cash flow per share is CHF5.01. Operating margins and revenue growth improved in FY2024, with net income growth 5.80% year-over-year, supporting the premium multiple versus sector averages.

GALD.SW stock: Technical snapshot

Momentum indicators show cooling strength. RSI reads 43.84, below neutral. Bollinger bands sit CHF141.65 lower and CHF159.11 upper. Price is below the 50-day average CHF152.33 but above the 200-day average CHF141.71, signalling mixed trend. The stock shows short-term weakness inside a longer-term uptrend since IPO.

Meyka AI rates GALD.SW with a score out of 100

Meyka AI rates GALD.SW with a score out of 100: 75.12 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. The model highlights healthy cash flow but flags a high PE and near-term volatility.

GALD.SW stock: Forecasts, price targets and outlook

Meyka AI’s forecast model projects a 12-month target of CHF206.65, implying an upside of 43.73% versus the current CHF143.80. A nearer-term target is CHF165.00, reflecting momentum recovery and aesthetic segment strength. Conservatively, a downside support target sits near CHF130.00 on continued sector weakness. Forecasts are model-based projections and not guarantees.

GALD.SW stock: Risks and catalysts

Key catalysts include upcoming product launches, Injectable Aesthetics trends, and the next earnings release on 2026-07-23. Risks include margin pressure, high multiples, and consumer spending shifts in core markets. Debt metrics are moderate, with debt-to-equity 0.37, and interest coverage 5.21, reducing immediate balance-sheet risk but not removing execution risk.

Final Thoughts

GALD.SW stock shows active trading and a clear thesis. At CHF143.80, the stock trades on heavy volume and mixed technicals. Valuation is rich, with a PE near 71.54, but cash flow metrics and revenue growth support a constructive view. Meyka AI’s forecast model projects CHF206.65 over 12 months, implying 43.73% upside versus today. Our balanced scenario offers a base case target of CHF165.00 and a conservative support at CHF130.00. Investors should weigh short-term volatility against multi-year growth in dermatology and aesthetics. Meyka AI provides this AI-powered market analysis to help inform decisions, but these projections are model-based and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.